Oruka Therapeutics, Inc. is a biotechnology company.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-133.29M |
| Operating Margin | 0.00% |
| Return on Equity | -27.30% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.63 |
| Price-to-Book | 7.56 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.31M |
| Float | $51.05M |
| % Insiders | 1.36% |
| % Institutions | 87.84% |
Volatility is currently contracting